Bonuccelli, U, Ceravolo, R, Salvetti, S, D’Avino, C, Del Dotto, P, Rossi, G, Murri, L. Clozapine in Parkinson’s disease tremor. Effects of acute and chronic administration. Neurology 1997; 49(6): 1587–1590.CrossRefGoogle ScholarPubMed

Durif, F, Debilly, B, Galitzky, M, Morand, D, Viallet, F, Borg, M, Thobois, S, Brousolle, E, Rascal, O. Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology 2004; 62(3): 381–388.CrossRefGoogle Scholar

Gammon, D, Cheng, C, Volkovinskaia, A, Baker, GB, Dursun, SM. Clozapine: why is it so uniquely effective in the treatment of a range of neuropsychiatric disorders? Biomolecules 2021; 11(7): 1030.CrossRefGoogle Scholar

Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N Engl J Med 1999; 340(10): 757–763.CrossRefGoogle Scholar

Pollak, P, Tison, F, Rascol, O, Destée, A, Péré, JJ, Senard, JM, Durif, F, Bourdeix, I. Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 2004; 75(5): 689–695.CrossRefGoogle ScholarPubMed

Yaw, TK, Fox, SH, Lang, AE. Clozapine in parkinsonian rest tremor: a review of outcomes, adverse reactions, and possible mechanisms of action. Mov Disord Clin Pract 2016; 3(2): 116–124.CrossRefGoogle ScholarPubMed

AHFS Drug information, 2012. Bethesda: American Society of Health-System Pharmacists. Accessed on 27 October 2022 via www.medicinescomplete.com.Google Scholar

Clonazepam. In: Brayfield, A (Ed.), Martindale: The Complete Drug Reference. London: The Royal Pharmaceutical Society of Great Britain. Accessed on 27 October via www.medicinescomplete.com.Google Scholar

Clozapine. In: DRUGDEX® System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Accessed on 11 March 2023 via www.micromedexsolutions.com.Google Scholar

Connolly, BS, Lang, AE. Pharmacological treatment of Parkinson disease: a review. JAMA 2014; 311(16): 1670–1683.CrossRefGoogle ScholarPubMed

Divac, N, Stojanovic´, R, Vujovic´, KS, Medic´, B, Damjanovic´, A, Postran, M. The efficacy and safety of antipsychotic medications in the treatment of psychosis in patients with Parkinson’s disease. Behav Neurol 2016; 2016: 4938154.CrossRefGoogle Scholar

Emre, M, Ford, PJ, Bilgiç, B, Uç, EY. Cognitive impairment and dementia in Parkinson’s disease: practical issues and management. Mov Disord 2014; 29(5): 663–672.CrossRefGoogle ScholarPubMed

Factor, SA, Friedman, JH, Lannon, MC, Oakes, D, Bourgeois, K. Clozapine for the treatment of drug-induced psychosis in Parkinson’s disease: results of the 12 week open label extension in the PSYCLOPS trial. Mov Disord 2001; 16(1): 135–139.3.0.CO;2-Q>CrossRefGoogle ScholarPubMed

Fernandez, HH, Donnelly, EM, Friedman, JH. Long-term outcome of clozapine use for psychosis in parkinsonian patients. Mov Disord 2004; 19(7): 831–833.CrossRefGoogle ScholarPubMed

Fox, SH. Non-dopaminergic treatments for motor control in Parkinson’s disease. Drugs 2013; 73(13): 1405–1415.CrossRefGoogle ScholarPubMed

Friedman, JH, Koller, WC, Lannon, MC, Busenbark, K, Swanson-Hyland, E, Smith, D. Benztropine versus clozapine for the treatment of tremor in Parkinson’s disease. Neurology 1997; 48(4): 1077–1081.CrossRefGoogle Scholar

Hack, N, Fayad, SM, Monari, EH, Akber, U, Hardwick, A, Rodriguez, RL, Malaty, IA, Romrell, J, Shukla, AAW, McFarland, N, Ward, HE, Okun, MS. An eight-year clinic experience with clozapine use in a Parkinson’s disease clinic setting. PLoS One 2014; 9(3): e91545.CrossRefGoogle Scholar

Jann, MW, Grimsley, SR, Gray, EC, Chang, WH. Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 1993; 24(2): 161–176.CrossRefGoogle ScholarPubMed

Joint Formulary Committee. British National Formulary (online). London: BMJ Group and Pharmaceutical Press. Accessed on 27 October 2022 via www.medicinescomplete.com.Google Scholar

Klein, C, Gordon, J, Pollak, L, Rabey, JM. Clozapine in Parkinson’s disease psychosis: 5-year follow-up review. Clin Neuropharmacol 2003; 26(1): 8–11.CrossRefGoogle Scholar

Lee, HB, Hanner, JA, Yokley, JK, Appleby, B, Hurowitz, L, Lyketsos, CG. Clozapine for treatment-resistant agitation in dementia. J Geriatr Psychiatry Neurol 2007; 20(3): 178–182.CrossRefGoogle Scholar

Merims, D, Balas, M, Peretz, C, Shabtai, H, Giladi, N. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson’s disease psychosis. Clin Neuropharmacol 2006; 29(6): 331–337.CrossRefGoogle ScholarPubMed

Morgante, L, Epifanio, A, Spina, E, Zappia, M, Di Rosa, AE, Marconi, R, Basile, G, Di Raimondo, G, La Spina, P, Quattrone, A. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 2004; 27(4): 153–156.CrossRefGoogle ScholarPubMed

Pierelli, F, Adipietro, A, Soldati, G, Fattapposta, F, Pozzessere, G, Scoppetta, C. Low dosage clozapine effects on l-dopa induced dyskinesias in parkinsonian patients. Acta Neurol Scand 1998; 97(5): 295–299.CrossRefGoogle ScholarPubMed

Samudra, N, Patel, N, Womack, KB, Khemani, P, Chitnis, S. Psychosis in Parkinson disease: a review of etiology, phenomenology, and management. Drugs Aging 2016; 33(12): 855–863.CrossRefGoogle ScholarPubMed

Summary of Product Characteristics – Clozaril 25 mg tablets. Mylan. Electronic Medicines Compendium: Clozaril 25 mg Tablets – Summary of Product Characteristics (SmPC) – (emc). Accessed on 27 October 2022 via www.medicines.org.uk.Google Scholar

Teodorescu, A, Dima, L, Ifteni, P, Rogozea, LM. Clozapine for treatment-refractory behavioral disturbance in dementia. Am J Ther 2018; 25(3): e320–e325.CrossRefGoogle ScholarPubMed

Trosch, RM, Friedman, JH, Lannon, MC, Pahwa, R, Smith, D, Seeberger, LC, O’Brien, CF, LeWitt, PA, Koller, WC. Clozapine use in Parkinson’s disease: a retrospective analysis of a large multicentered clinical experience. Mov Disord 1998; 13(3): 377–382.CrossRefGoogle ScholarPubMed

Wang, J, Yu, J-T, Wang, H-F, Meng, X-F, Wang, C, Tan, C-C, Tan, L. Pharmacological treatment of neuropsychiatric symptoms in Alzheimer’s disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2015; 86(1): 101–109.CrossRefGoogle ScholarPubMed

Wilby, KJ, Johnson, EG, Johnson, HE, Ensom, MHH. Evidence-based review of pharmacotherapy used for Parkinson’s disease psychosis. Ann Pharmacother 2017; 51(8): 682–695.CrossRefGoogle ScholarPubMed